Xianning Lai, Sarah Kit Leng Lui, Hiu Yan Lam, Yuta Adachi, Wen Jing Sim, Natali Vasilevski, Nicola J Armstrong, Stephanie Claire Bridgeman, Nathan Michael Main, Tuan Zea Tan, et al. SHP2 inhibitors maintain TGFβ signalling through SMURF2 inhibition. NPJ precision oncology. 2023. 7. 1. 136-136
Yuta Adachi, Ryo Kimura, Kentaro Hirade, Shogo Yanase, Yuki Nishioka, Natsumi Kasuga, Rui Yamaguchi, Hiromichi Ebi. Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS. Nature cancer. 2023. 4. 6. 829-843
Jinyang Cai, Sheeba Jacob, Richard Kurupi, Krista M Dalton, Colin Coon, Patricia Greninger, Regina K Egan, Giovanna T Stein, Ellen Murchie, Joseph McClanaghan, et al. High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition. Cell reports. 2022. 40. 4. 111095-111095
Wenjing Su, Radha Mukherjee, Rona Yaeger, Jieun Son, Jianing Xu, Na Na, Neilawattie Merna Timaul, Jaclyn Hechtman, Viktoriya Paroder, Mika Lin, et al. ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. Molecular cell. 2022. 82. 13. 2443-2457
Yuta Adachi, Ryo Kimura, Kentaro Hirade, Hiromichi Ebi. Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers. Cancers. 2021. 13. 20
Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang, Keiko Tanimura, Akihiro Nishiyama, Azusa Tanimoto, Yuta Adachi, Shinji Takeuchi, Hiroyuki Yamaguchi, Minoru Fukuda, et al. AXL confers intrinsic resistance to osimertinib and the emergence of tolerant cells. CANCER RESEARCH. 2019. 79. 13
谷口 寛和, 山田 忠明, 王 融, 谷村 恵子, 足立 雄太, 西山 明宏, 谷本 梓, 竹内 伸司, 山口 博之, 高山 浩一, et al. オシメルチニブに対する初期耐性と治療抵抗性細胞の出現へのAXLの関与(AXL confers intrinsic resistance to osimertinib and the emergence of tolerant cells). 日本癌学会総会記事. 2018. 77回. 185-185
